Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 33 of 36.
Apr 2010
29 Apr · Business
Press release dated April 29, 2010, titled "Zydus Cadila's Net Profit zooms by 67% in FY'10 ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Apr · Dividend
Board of Directors of the Company at its meeting held on April 29, 2010 have recommended a dividend of Rs.5/- per equity share (@ 100%) on the increased capital of 204,748,520 equity shares (including 69,249,507 Bonus equity shares) of Rs.5/- each for the financial year ended on March 31, 2010.29 Apr · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 183293 lacs for year ending on 31-MAR-2010 against Rs. 169852 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 50327 lacs for the year ending on 31-MAR-2010 against Rs. 26591 lacs for the year ending on 31-MAR-2009.29 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 42575 lacs for quarter ending on 31-MAR-2010 against Rs. 43061 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 13099 lacs for the quarter ending on 31-MAR-2010 against Rs. 4257 lacs for the quarter ending on 31-MAR-2009.29 Apr · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 357418 lacs for year ending on 31-MAR-2010 against Rs. 286240 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 50514 lacs for the year ending on 31-MAR-2010 against Rs. 30308 lacs for the year ending on 31-MAR-2009.29 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 81589 lacs for quarter ending on 31-MAR-2010 against Rs. 70255 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 11876 lacs for the quarter ending on 31-MAR-2010 against Rs. 5800 lacs for the quarter ending on 31-MAR-2009.28 Apr · Business
Press release dated April 28, 2010, titled "Zydus receives approval for Tamsulosin capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Apr · Results
We hereby confirm that our Company shall provide to the Exchange audited financial results within a stipulated period of 60 days from the end of financial year i.e. 31st March 201012 Apr · Corporate action
The Bonus Committee of the Board of Directors at its meeting held to-day i.e. 9th April, 2010 made allotment of 6,82,49,507 equity shares of Rs.5/- each fully paid-up as Bonus Shares in the ratio 1 (One) new Bonus Equity Shares for every 2 (Two) Equity Shares to the members holding physical shares as on the 'Record Date' i.e. 6th April, 2010 and to the members holding shares in electronic form as per the details of beneficiaries furnished by NSDL/CDSL for the purpose, in accordance with the approval of the members at the Extra Ordinary General Meeting held on 22nd March 20108 Apr · Change in Registrar & Share Transfer Agent
Company has appointed M/s. Sharepro Services (India) Pvt. Ltd. (Sharepro) having its Registered Office at 13AB, Samhita Warehousing Complex, Sakinaka Telephone Exchange Lane, Off Andheri Kurla Road, Sakinaka, Mumbai - 400 072 as Share Transfer Agent in place of M/s. Pinnacle Share Registry Pvt. Ltd. w.e.f. April 01, 2010 for a period of 3 years on the terms and conditions mentioned in the Memorandum of Understanding (MOU) made between the Company and the Sharepro on April 06, 2010.7 Apr · Board meeting
To consider amongst others audited financial results for the year ended March 31, 2010 and for recommendation of dividend.
Mar 2010
22 Mar · Corporate action
Committee of Board of Directors of the Company at its meeting held on March 22, 2010 has fixed April 06, 2010 as Record Date for the purpose of determining the members entitles to Bonus equity shares as recommended by the Board and approved by the shareholders in proportion of one new equity share of Rs.5/- each fully paid-up for every two equity shares of Rs.5/- each fully paid-up held by them.22 Mar · Meeting
Proceedings of the Extra Ordinary General Meeting of the members of the Company held on March 22, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Mar · Business
Press release dated March 4, 2010, titled "Zydus commences Phase II and III clinical trials of its H1N1 vaccine". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Mar · Meeting
Notice of the Extraordinary General Meeting of the members of the Company to be held on March 22, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
25 Feb · Business
Press release dated February 25, 2010, titled "CHL announces Bonus Shares in the ratio of 1:2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Feb · Corporate action
Board of Directors of the Company at their meeting held on February 25, 2010 have taken the following decisions. (1) To increase the authorised share Capital from existing Rs.700/- Millions to Rs.1100/- Millions and; (2) To issue bonus equity shares in the ratio of One equity share of Rs.5/- each fully paid-up for every Two equity shares of Rs.5/- each held by the shareholders of the Company on the Record Date to be fixed by the Board of Directors/Committee of the Board, subject to the approval of the shareholders and; (3) To convene Extra Ordinary General Meeting of Shareholders on March 22, 2010 for the purpose.22 Feb · Board meeting
To Consider the proposal of issuing Bonus Equity shares.17 Feb · Business
Press release dated February 17, 2010, titled " Mr. Pankaj R. Patel, CMD- Zydus Cadila, wins E&Y Entrepreneur of the year - Healthcare and Life Sciences Award 2009". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
25 Jan · Business
Press release dated January 25, 2010, titled "Zydus Cadila's Net Profit up by 114 % in Q3". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 46040 lacs for quarter ending on 31-DEC-2009 against Rs. 36810 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 12532 lacs for the quarter ending on 31-DEC-2009 against Rs. 7224 lacs for the quarter ending on 31-DEC-2008.25 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 96540 lacs for quarter ending on 31-DEC-2009 against Rs. 73627 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 12967 lacs for the quarter ending on 31-DEC-2009 against Rs. 6053 lacs for the quarter ending on 31-DEC-2008.8 Jan · Board meeting
To consider, amongst others, unaudited financial results for the quarter / nine months period ended December 31, 2009.4 Jan · Business
Press release dated January 04, 2010, titled " Zydus Cadila to start clinical trials of H1N1 vaccine." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
31 Dec · Business
Press release dated December 31, 2009, titled "Simayla becomes a 100% subsidiary of the Zydus Group." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
27 Oct · Results
Standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 94678 lacs for half year ending on 30-SEP-2009 against Rs. 89985 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 24696 lacs for the half year ending on 30-SEP-2009 against Rs. 15114 lacs for the half year ending on 30-SEP-2008.27 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 48151 lacs for quarter ending on 30-SEP-2009 against Rs. 47072 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 12440 lacs for the quarter ending on 30-SEP-2009 against Rs. 9550 lacs for the quarter ending on 30-SEP-2008.27 Oct · Results
Consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 179289 lacs for half year ending on 30-SEP-2009 against Rs. 142358 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 25671 lacs for the half year ending on 30-SEP-2009 against Rs. 18455 lacs for the half year ending on 30-SEP-2008.27 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 91258 lacs for quarter ending on 30-SEP-2009 against Rs. 73785 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 13192 lacs for the quarter ending on 30-SEP-2009 against Rs. 9488 lacs for the quarter ending on 30-SEP-2008.27 Oct · Business
Press release dated October 27, 2009, titled "Zydus Cadila registers 39% increase in Net Profit in Q2". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Oct · Board meeting
To consider amongst others unaudited financial results for the quarter/ half-year ended September 30, 2009.
Sep 2009
23 Sep · Rating
CRISIL has, after due consideration, reaffirmed the P1+" (pronounced "P one plus") rating for the 1,250 million Short Term Debt Programme of the Company. This indicates that the degree of safety with regard to timely payment of interest and principal on the instrument is very strong.
Aug 2009
12 Aug · Meeting
Proceedings of the Annual General Meeting of the shareholders of the Company held on July 29, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Aug · Rating
Letter bearing reference no. AC/CR/CHL/2009/CH3950 dated July 23, 2009 issued by CRISIL Rating for the Rs.1250 million Short Term Debt Programme (including Commercial Paper Programme) of the Company enhanced from Rs.600 million.
Jul 2009
29 Jul · Management
Mr. Homi K. Bilpodiwala, director of the Company who was liable to retire by rotation at the Annual General Meeting of the Company held on July 29, 2009 had not offered himself for re-appointment. In view of the same, Mr. Homi K. Bilpodiwala ceased to be a director of the Company w.e.f. July 29, 2009 after conclusion of the Annual General Meeting.27 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 46527 lacs for quarter ending on 30-JUN-2009 against Rs. 48213 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12256 lacs for the quarter ending on 30-JUN-2009 against Rs. 5564 lacs for the quarter ending on 30-JUN-2008.27 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 88031 lacs for quarter ending on 30-JUN-2009 against Rs. 68571 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12479 lacs for the quarter ending on 30-JUN-2009 against Rs. 8968 lacs for the quarter ending on 30-JUN-2008.27 Jul · Business
Press release dated July 27, 2009, titled "Zydus Cadila Q1 Net Profit surges by 39%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Jul · Dividend
Company shall make the payment of dividend on equity shares of the Company on or after August 04, 2009 as may be approved by the members at the Annual General Meeting of the Company to be held on July 29, 2009. Further, the Board of Directors has recommended dividend of Rs. 4.50 (90%) per equity share of the face value of Rs.5/- each.13 Jul · Business
Press release dated July 13, 2009, titled "Zydus Cadila and Karo Bio's research collaboration has generated promising lead compounds". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Jul · Board meeting
Meeting on 27 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Jun 2009
9 Jun · Updates
Investors' Presentation to be made at UBS Global Speciality Pharmaceuticals Conference-2009 at London by Dr. Sharvil P. Patel, Deputy Managing Director of the Company. A copy of the presentation shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Jun · Business
Press release dated June 04, 2009, titled "Zydus files IND application with the DCGI for 'ZYD1' - a novel candidate to treat Diabetes and Obesity". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
19 May · Updates
CRISIL has reaffirmed the "P1+" (pronounced "P one Plus") rating for Rs.600/- million Short Term Debt Programmed of the Company. The rating indicates that the degree of safety with regard to timely payment of interest and principal on the instrument is very strong.19 May · Meeting
Register of Members in respect of Equity Shares of the Company shall remain close from July 20, 2009 to July 29, 2009 (both days inclusive) to determine the entitlement of membership of the Company for payment of dividend as may be declared by the members at the 14th Annual General Meeting of the Company to be held on July 29, 2009.5 May · Business
Press release dated May 05, 2009, titled "Zydus receives approval for Mycophenolate Mofetil tablets and capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
29 Apr · Management
Auditor's Report in respect of the audited financial results for the quarter and year ended March 31, 2009. A copy of the Auditor's Report shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Updates
Statement of Appropriations pursuant to clause 20 of the Listing Agreement in respect of Annual Audited Financial Results of the Company for the year ended March 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Dividend
Board of Directors of the Company at its meeting held on April 28, 2009 recommended the declaration of dividend Rs. 4.50 per Equity Share i.e. 90% on 13,64,99,013 equity shares of Rs. 5/- each of the Company for the year ended March 31, 2009.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 43061 lacs for quarter ending on 31-MAR-2009 against Rs. 40320 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 4257 lacs for the quarter ending on 31-MAR-2009 against Rs. 3540 lacs for the quarter ending on 31-MAR-2008.